| |NOVEMBER 20259SAI LIFE SCIENCES EXPANDS WITH NEW R&D FACILITY IN HYDERABADTELANGANA TARGETS 1 LAKH CR LIFE SCIENCES INVESTMENT BY 2030According to Minister for IT and Industries Duddilla Sridhar Babu, Telangana has set the lofty goal of bringing in Rs. 1 lakh crore in new investments in the life sciences sector by 2030 in order to create jobs for five lakh people.The Minister stated that the State government has created a thorough "Roadmap 2030" to establish Telangana as a Global Life Sciences Hub while giving the keynote lecture at the AusBiotech International Conference 2025 in Melbourne, which is being organized in collaboration with the Government of Victoria."Telangana is preparing a Comprehensive Life Sciences Policy to accelerate innovation, infrastructure, and global partnerships," Sridhar Babu said, outlining the State's strategy for the next phase of bio-digital growth.The State has received new investments of Rs. 3.2 lakh crore over the last 20 months, of which Rs. 63,000 crore have come from the Life Sciences sector alone.In 2024, the sector's exports exceeded Rs. 26,000 crore from April to December. According to the Minister, Telangana wants to boost the value of its life sciences sector from US$80 billion to US$250 billion by 2030.Babu cited a research from the international consulting firm CBRE, which stated that Hyderabad, along with Boston, San Francisco, Cambridge, Beijing, and Tokyo, is included as one of the world's top life sciences clusters in the Global Life Sciences Atlas 2025. He went on to say that Hyderabad is the only Indian city on this list. The city's lease of life sciences offices increased from 0.6 million square feet in 2022 to 2.4 million square feet in 2024, demonstrating the industry's explosive growth and investor confidence. POSai Life Sciences Limited, among India's fastest growing Contract Research, Development and Manufacturing Organizations (CRDMO), is announcing the ground breaking of a CMC Process R&D Center at its integrated R&D campus in Hyderabad.The facility is expected to be completed by September 2026 and will double the company's Process R&D capacity, while offering additional process R&D in peptide development, oligo intermediates & linkers development, formulation development and early phase clinical supply services.Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: "As our partners seek greater speed, flexibility, and scientific depth, we are scaling our capabilities to move programs faster and more efficiently through the development continuum. In an environment where timelines are continually compressing, this new center enhances our ability to combine scientific excellence with execution agility." The new CMC Process R&D Center is a strategic investment in scale, sustainability and specialization. The new R&D Center will offer support for Full-Time Equivalent (FTE) and Dedicated Project Capacity (DPC) engagement models, enabling flexible collaboration with global innovators-from early development through to late stage CMC programs.This engagement model will further bolster Sai Life Sciences' preferred partner position for integrated drug development, attesting to the growing global demand for end-to-end, partnership driven solutions, and delivery of quality and timelines. This investment is a part of the company's planned capital expenditure, and is a testament to the strong business momentum and expanding partnership with global pharmaceutical and biotech partners.The capex is guided by growing demand for larger clinical-scale programs, a robust late-stage development pipeline, and the need for scalable capacity across CMC development and manufacturing. PO
< Page 8 | Page 10 >